Brought to you by 
Genentech pays $725mm up front for early-stage cancer start-up Seragon
Jul 2014
Executive Summary
Roche’s Genentech Inc. shelled out $725mm in up-front cash to buy privately held Seragon Pharmaceuticals Inc., an early-stage oncology company that could also get up to $1bn in earn-outs.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Payment Includes Cash
- Acquisition of Private Biotech
- Full Acquisition
- Intra-Biotech Deal
- Includes Earnout
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genentech pays $725mm up front for early-stage cancer start-up Seragon
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice